Page last updated: 2024-08-23

plicamycin and Leukemia, Promyelocytic, Acute

plicamycin has been researched along with Leukemia, Promyelocytic, Acute in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fraizer, GC; Ghimirey, N; Kuerbitz, SJ; Moazam, M; Pandey, S1
Cotter, TG; Duverger, V; England, K; Hayes, I; Murphy, AM; Murphy, FJ; Sheehan, D1

Other Studies

2 other study(ies) available for plicamycin and Leukemia, Promyelocytic, Acute

ArticleYear
WT1 regulates cyclin A1 expression in K562 cells.
    Oncology reports, 2019, Volume: 42, Issue:5

    Topics: Adolescent; Binding Sites; Cell Proliferation; Cell Survival; Child; Child, Preschool; Curcumin; Cyclin A1; Female; Gene Expression Regulation, Neoplastic; Humans; Infant; K562 Cells; Leukemia, Promyelocytic, Acute; Male; Plicamycin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Promoter Regions, Genetic; Up-Regulation; WT1 Proteins

2019
The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF).
    British journal of cancer, 2004, May-17, Volume: 90, Issue:10

    Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Carrier Proteins; Drug Resistance, Neoplasm; fas Receptor; Fas-Associated Death Domain Protein; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Promyelocytic, Acute; Plicamycin; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha

2004